Sayaji Hotels - Rs.49.00

Established in 1982 and promoted by the Dhanani family of Indore, Sayaji Hotels Ltd. (Sayaji) currently manages two 3 star hotel properties, one each in Vadodra (Baroda) and Indore. Located in the heart of city, the Indore Hotel is the flagship hotel and enjoys good patronage. It has 230 rooms and suites, 5 restaurants, 9 banquets and wedding halls, a health and fitness club, pub & discotheque, state-of-the-art Quorum lounge, a full-fledged club and entertainment centre with swimming pool, bowling alley, lawn tennis, golf, virtual games, squash, billiards, saloon and spa etc. On the other hand, its Vadodra property has 73 rooms with 3 restaurants and 5 banquet halls. To a large extent, Sayaji is immune to the cyclical nature of the hotel industry as most of its occupants are business travellers. Interestingly, its ratio of food & beverages (F&B) sales to room sales is 1.6 times as against, the industry norm of 0.7. Presently, Sayaji enjoys 75% and 12% market share in Indore and Vadodara respectively.

To cash in on the booming hotel industry, Sayaji is coming up with a hotel project in Pune, for which it has recently signed a MOU to purchase land admeasuring 1,80,000 sq. ft on Banglore-Mumbai Express highway. This Rs.95 cr. project will comprise 200 rooms, 100 service apartments, 3 F&B outlets and 5 Banquet Halls. Further, it is planning to build a 360 room 5 Star hotel in Bangalore at an investment of about Rs.120 cr. It has also ventured into the retail sector and has started a multi cuisine restaurant at Pali Hill, Mumbai with the brand name ‘Barbeque Nation’. It has plans to set up more such restaurants in Mumbai at Lokhandwala, Worli, Chembur and Navi Mumbai by the end of 2006. Sayaji is working towards establishing a chain of 100 restaurants across major cities in India with a capex of Rs.50 cr. in the next two years. This means that the company’s revenue growth is going to be driven by F&B outlets as well.

To fund its expansion plans the company has finalized to issue Foreign Currency Convertible Bond (FCCB) of up to US $8 million to Clearwater Capital Partners (Cyprus) Ltd. and fresh 34.15 lakh equity shares on preferential basis to promoters and high net worth investors at a rate of Rs.66 per share. Incidentally, Sayaji has virtually has no tax liability due to previous accumulated losses and subsidy from Department of Tourism (DOT), which is expected to continue for the next two years at least. For FY07, it is expected to report total revenue of around Rs.50 cr. and net profit of around Rs.7 cr. resulting in an EPS of Rs.8 on its current equity of Rs.8.60 cr. On partly diluted equity of Rs.12.50 cr. (i.e. excluding FCCB) its EPS comes to Rs.5.50, whereas on full diluted equity of Rs.18 cr. the EPS works out Rs.4. With average room rate (ARR) and occupancy rates on the rise coupled with its aggressive retail expansion, Sayaji is expected to perform much better in coming years. Investors can accumulate this scrip at sharp dips with a price target of Rs.75 (70% appreciation) in 12-15 months.

STOCK WATCH

More than five decades old, Delton Cables (Code No.: 504240) (Rs.82.75) is one of the largest manufacturers of cables and offers Total Telecom Solution Products- from conventional telecom cables to microwave accessories etc. It is a prime supplier to the Power, Telecommunication, Railways, Steel and Mining sectors in India and has firmly established itself in the international market. For FY06, its turnover grew by almost 50% to Rs.100 cr. but its net profit jumped 370% to Rs.3.50 cr. resulting in an EPS of Rs.12 on its tiny equity of Rs.2.88 cr. It can easily report an EPS of Rs.14 for FY07. Where other cable company shares are richly discounted by 12-14 times, this share is available below 6 times its forward PE. Although, no dividend is a cause of concern, still with its recent high of Rs.150, the scrip can easily double in 15-18 months.

Bilpower (Code No.: 531590) (Rs.90.35) is the pioneer in the field of manufacturing all types of Transformers, Electrical Laminations, Stampings and Cores. In fact, it is the leading trader of CRGO & CRNGO and produces the largest range of ready-to-assemble cores for distribution transformer in India. It reported stunning numbers for the year ending 31st March 2006. Sales have more than doubled to Rs.126 cr. whereas PAT spurted 165% to Rs.11 cr. registering an EPS of Rs.18 on its current equity of Rs.6 cr. For FY07, it is expected to clock a turnover of more than Rs.150 cr. with net profit of Rs.13.50 cr. This translates into an EPS of Rs.15 on its fully diluted equity of around Rs.9 cr. To fund its expansion, the company has already allotted 4 lakh warrants to be converted into equity at Rs.97 per share. Its share price has the potential to hit a new high of above Rs.180 in next 15-18 months.

After hitting Rs.166 on 2nd May’06, FCS Software (Code No.: 532666) (Rs.80.80) was badly beaten down to Rs.66 on 14th June’06. Notably in September’05, the company had allotted 35 lakh shares at Rs.50 per share through a public offering. The company is primarily a niche player in core IT areas like e-learning, digital content services, IT consultancy and product engineering services. It reported encouraging numbers for FY06 with top-line registering 40% growth at Rs.116 cr. and net profit rising 60% to Rs.15 cr. This works out to an EPS of Rs.11 on its expanded equity of Rs.14 cr. It declared 15% dividend. Once the market sentiment changes, this scrip will immediately shoot up to Rs.110-120 levels. A good bet in the IT sector.

In the recent carnage, Ind-Swift Labs (Code No.: 532305) (Rs.78.75) is one scrip which has become one third from its 52W high of Rs.236. It is one of the largest manufacturers of Clarithromycin in the world and enjoys 30% to 33% of the world capacity for this drug. Importantly, the company has also already received TGA (Therapeutic Goods Administration) certification and EDQM (European Directorate for the Quality of Medicines) certification for Clarithromycin which gives it access for exports to regulated markets. Also, tap the regulated markets of US, Japan & Australia; it has already filed over 7 DMFs in USA and over 50 DMFs in other European countries. The Company has also filed 13 patents for non-infringing processes for its products in USA & India. Moreover, the company has recently launched four new APIs which are Letrozole (Aromtase Inhibitor), Quetiapine Fumerate (Anti-Psychotic), Aripiprazole (Anti-Pshycotic) & Ropinirole (Parkinson Disease). In short, a great buy in the pharma sector.

Although Aarvee Denim (Code No.: 514274) (Rs.71.70) may not declare so goods numbers for March’06 quarter on 28th June due to lower price realization, still it is a strong buy at current levels. The company is implementing an aggressive expansion plan to increase its production capacity by 50% to 72 million metres per month. It is also planning to launch its own brand name ‘ADEN’ in Ahmedabad, Delhi and Mumbai initially. It may end FY06 with sales of Rs.280 cr. and net profit of Rs.35 cr. which may rise to Rs.320 cr. and Rs.42 cr. respectively for FY07. This would mean an EPS of Rs.18 for FY07 on its fully diluted equity of about Rs.23.50 cr. At a reasonable discounting by 7-8 times, the scrip should trade in the range of Rs.130-150. A screaming buy with a very nominal downward risk.

Wanbury Ltd - Rs.72.00

Wanbury Ltd was formed with the merger of Pearl Organics and Wander Ltd. in October’03. Pearl Organics is an API manufacturer focused on the regulated US/ European markets whereas Wander is an ethical formulations company focused on branded formulations in the domestic market. The key bulk drugs manufactured by the company are Gabapentin, Metformin, Ibuprofen, Glucosamine, Salsalate, Mefenamic acid etc. Wanbury is the world’s largest producer of Metformin - a diabetes management product with exports to more than 50 countries. Most of the leading global generic players in regulated markets like Apotex, Mylan, Torr, Barr, Teva, Dexxon, Pliva etc source their product from Wanbury and around 65% of its exports are to regulated markets. In the formulations business, company’s product profile comprises of Gynaecology, Orthopaedic Pediatrics, Nurtrition etc. This division boasts of 450 professionals, 18 brands, 24 distributors and about 1200 stockists across the country.

Wanbury has three manufacturing facilities spread across Patalganga & Tarapur in Maharashtra and Tanuku in Andhra Pradesh. Of these, its Patalganga and Tanuku facilities are USFDA approved for multi-products. It has also set up two hi-tech R&D centres: one in Turbhe, Navi Mumbai, for API and another at Chembur, Mumbai, for formulations. Notably, the company already has 4 Drug Master Files (DMFs) in the US and 2 in Europe, whereas lately it has filed for 4 more DMFs with USFDA in the field of Cardiovasculars, Central Nervous System, Anti-Inflammatory Segment. In the coming few months, it is expected to file 10-15 DMFs further. On the formulation front, Wanbury launched 'Coriminic' range of cough and cold formulations for Pediatric use, which has been well-received in the market. Under the expansion plan, the company has just completed its first phase and commissioned a new unit at Tanuku to manufacture three high value products: Sertraline, Paroxetine and Carvedilol, which have a strong market. The second phase of expansion would be completed by August’06 in which 4-6 new products would be added to the existing product portfolio.

Wanbury continues to grow organically as well as inorganically and has acquired Pharmaceutical Products India Ltd., an API manufacturer. It has a facility at Tarapur and another large partly finished facility at Patalganga, which is meant for regulated markets and will be USFDA compliant. Besides, Wanbury has also taken 51% stake in Doctors Organic Chemical Ltd. (DOCL) - another API making company that will enable Wanbury to foray into contract manufacturing for the regulated markets. DOCL has a USFDA approved facility for the manufacture of non-sterile APIs where it manufactures ibuprofen, mefenamic acid, glucosamine and gabapentene and is a contract manufacturer for leading global pharma companies like Pfizer to which it supplies gabapentene intermediate and mefenamic acid. Further, Wanbury is close to acquiring a branded generics company in the UK, which will be its first overseas acquisition and will strengthen its international presence. With all these expansions and acquisitions, Wanbury is estimated to grow phenomenally in coming years and may report Sales of Rs.150 cr. and net profit of Rs.16 cr. for FY07. This translates into EPS of Rs.13 on its equity of Rs.12.75 cr. Hence investors are strongly recommended to buy at current levels to double their money in 12-15 months. With 52W high at Rs.200, it’s a safe bet.

Upper Ganges Sugar - Rs.172.00

Incorporated in 1932, Upper Ganges Sugar & Industries Ltd. (UGSIL) is the flagship sugar venture of the K.K. Birla Group, which has diversified interests in key industries like fertilizers, chemicals, sugar, heavy engineering, textiles, shipping, newspaper publishing, etc. Having a rich experience of more than seven decades and facing all ups and downing the sugar industry, UGSIL is one of the oldest and best sugar mills in India. Apart from sugar, the company also generates revenue from byproducts like molasses, bagasse, industrial alcohol, ethanol etc. It has also installed a Bio Compost Plant to produce organic fertilizer which is marketed under the brand name ‘Uttam Jaivik Khad’ and a tea estate by the name of ‘Cinnatolliah Tea Garden’ spread over 746 hectares in North Lakhimpur, Assam.

After acquisition of a sugar mill from group company, New India Sugar Mills Ltd. in 2004, UGSIL currently has three sugar plants, one in UP and two in Bihar, with a total capacity of 14,500 TCD. Its main plant i.e. Seohara Sugar Mills is located in UP and has a crushing capacity of 10,000 tonnes of sugarcane per day. This plant also has distillery unit with a capacity of producing 16.50 million litres per annum of Industrial Alcohol/Ethanol. Its other two plants in Bihar are Bharat Sugar Mills with a capacity of 2500 TCD and Hasanpur Sugar Mills with 2000 TCD capacity. Due to various fiscal benefits offered by the Bihar government and the strong uptrend in the sector, company is expanding its Bharat Sugar mill capacity to 5000 TCD with a sulphur free sugar refinery and is also setting up 18 MW co-generation plant thru a capex of Rs.125 cr. In view of the increasing demand for electricity and to provide for more remunerative utilization of bagasse, UGSIL is putting up a 24 MW co-generation plant at its UP mill for export and captive use at an estimated capital outlay of about Rs.100 cr. Moreover, to meet the increasing demand for ethanol, the company has undertaken expansion of the distillery unit from the existing capacity of 55 klpd to 100 klpd at an estimated cost of Rs.36 cr. For future growth, UGSIL is also contemplating a greenfield integrated sugar complex in UP having a capacity of 7000 TCD with a co-generation power plant and refinery. Post all its expansion, the company’s total capacity will stand enhanced to about 23000 TCD.

To part-finance its expansion plan, the company recently came out with a rights issue in the ratio of 13 shares for 20 shares held at Rs.150 per share. Currently, the scrip is trading ex-right and is available at around Rs.170 per share. For FY06 ending 30th June’06, company is expected to clock a turnover of more than Rs.400 cr. and PAT of around Rs.30 cr. This will work out to an EPS of Rs.26 on its fully expanded equity of Rs.11.55 cr. and may declare 50% dividend for FY06. For FY07, it may record Sales and net profit of Rs.525 cr. and Rs.40 cr. respectively which would mean an EPS of Rs.35. Hence at a reasonable discounting of 8 times, its share price has the potential to hit Rs.280 (60% appreciation) in 12-15 months.

STOCK WATCH

Nectar Life Science (Code No.: 532649) (Rs.104.55) is among the largest manufacturers and exporters of Cephalosporins-antibiotic used to treat bacterial infections and Semi Synthetic Penicillins. In fact, it is among the few life saving API manufacturing companies with facilities to produce sterile APIs through both Lyophilization and Crystallization processes. Recently, it filed Drug Master File (DMF) for one of its Oral Cephalosporin Active Ingredient both with USFDA and EDQM which is the first step towards moving into regulated and lucrative markets like USA & EU. It is expected to file around 7-8 DMFs in the current fiscal. Couple of months back, it raised around Rs.160 cr. through the FCCB route at Rs.332 per share but currently the scrip is available below Rs.100. For FY06, it may clock turnover of Rs.290 cr. with net profit of Rs.22 cr. i.e. EPS of Rs.11 on the fully diluted equity of around Rs.20 cr. For FY07, it can post an EPS of Rs.14. Hence the scrip has the potential to double in a year’s time. Best time for long-term investors to buy this scrip.

APW President (Code No.: 590033) (Rs.107.35) manufactures and markets a wide range of enclosures and cabinets under the brand name ‘President’ for telecommunications, general electronics, networking, industrial purpose etc. Due to the robust demand the company is expanding its Bangalore facility and is also setting up a greenfield project in SEZ to cater to Telecom, Electronics and Data Com/ Kiosk business. To fund its expansion, the company is planning to raise capital through equity route, which will trigger the share price in the near future. It may end FY06 with sales of Rs.75 cr. and net profit of Rs.6.50 cr. i.e. an EPS of Rs.11 on its current equity of Rs.6.05 cr. With its 52W high at Rs.214, the scrip has the potential to give handsome returns in the medium to long-term.

Gemini Communication (Code No.: 532318) (Rs.371.05) is the first and only company in India designing and manufacturing RFid products. It makes RFid-based readers and antennas under the brand ‘Traze’ with technology assistance from Texas Instruments. Moreover, it is India’s largest Wireless Solution Provider (WSP) on the ‘Last Mile’ to corporates for intra-city communications and to ISP’s for internet connectivity. For FY06, its top-line grew by 78% to Rs.126 cr. but its net profit jumped 150% to Rs.11.75 cr. registering a EPS of Rs.27. Importantly, it is expected to grow extraordinarily in coming years and may report a top-line and bottom-line of Rs.225 cr. and Rs.25 cr. respectively for FY07. This means an EPS of Rs.52 on its diluted equity of Rs.4.88 cr. Hence scrip can easily double in a 12-15 months. Moreover, the company is going in for a stock split, which will further trigger the share price.

Belonging to the TVS group, Harita Seating Systems Ltd. (Code No.: 590043) (Rs.145) provides seating solutions in commercial vehicles, buses/coaches, agriculture tractors, construction machinery, two wheelers, three wheelers, cars, multi-utility vehicles etc. It has also developed public seating for auditoriums and theatres. To cater to the rising demand, the company is setting up a unit in Himachal Pradesh for the manufacture of seats for two wheelers, bus passenger vehicles and tractors at an estimated cost of Rs.7.5 cr. For FY06, its turnover increased by 16% to Rs.137 cr. but its net profit spurted 35% to Rs.6.20 cr. thereby reporting an EPS of Rs.16 on its small equity of Rs.3.90 cr. For FY07, it can post an EPS of Rs.21, which means the scrip is available at a forward PE of just 7 times. A solid buy.

GM Breweries (Code No.: 507488) (Rs.88.15) enjoys a virtual monopoly in country liquor in the districts of Mumbai and Thane as it is the single largest manufacturer in Maharashtra. It is working at 75% capacity utilization and has tremendous opportunity to penetrate into interior districts taking advantage of its brand image. For FY06, its sales increased by 115% to Rs.155 cr. whereas its net profit shot to Rs.13.40 cr. compared to Rs.0.73 cr. last year due to better operating efficiency. This translates into an EPS of Rs.14 on its equity of Rs.9.36 cr. But the more interesting aspect is its rising operating profit margin with every passing quarter. Assuming the same trend, it can report sales of Rs.185 cr. and net profit of Rs.20 cr. i.e. EPS of Rs.21 for FY07. Reasonable discounting it by 14 times, its share price can touch Rs.300 mark. At the current market cap of Rs.80 cr. it’s a screaming buy.